Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 23/11/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Dermatitis, Atopic, Date of authorisation: 16/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Hodgkin Disease;Lymphoma, Non-Hodgkin, Date of authorisation: 18/07/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor,ivacaftor, Cystic Fibrosis, Date of authorisation: 31/10/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Diabetes Mellitus, Date of authorisation: 26/06/2000, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Talvey, talquetamab, Multiple Myeloma, Date of authorisation: 21/08/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voxzogo, vosoritide, Achondroplasia, Date of authorisation: 26/08/2021, Revision: 4, Status: Authorised

Azamethiphos (extension to fin fish): European public maximum-residue-limit assessment report (EPMAR)

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, Online, from 19/09/2023 to 20/09/2023

Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 6-9 November 2023